Skip to main content
Top
Published in: Trials 1/2020

Open Access 01-12-2020 | Study protocol

MOdified DIagnostic strateGy to safely ruLe-out pulmonary embolism In the emergency depArtment: study protocol for the Non-Inferiority MODIGLIANI cluster cross-over randomized trial

Authors: Anne-Laure Philippon, Margaux Dumont, Sonia Jimenez, Sarah Salhi, Marine Cachanado, Isabelle Durand-Zaleski, Tabassome Simon, Yonathan Freund

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Introduction

In the work-up strategy for pulmonary embolism (PE) in the ED, the recently introduced YEARS rule allows the raising of the D-dimer threshold to 1000 ng/ml in patients with no signs of deep venous thrombosis and no hemoptysis and in whom PE is not the most likely diagnosis. However, this decision rule has never been prospectively compared to the usual strategy. Furthermore, it is unclear if the YEARS rule can be used on top of the Pulmonary Embolism Rule-out Criteria (PERC). We aim to assess the non-inferiority of YEARS compared to current guidelines to rule out PE among PERC-positive ED patients with suspicion of PE.

Methods/design

The MODIGLIANI study is a multicenter, European, non-inferiority, cluster-randomized, two periods cross-over, controlled trial. Each center will be randomized for the sequence of two 4-month periods: intervention (MOdified Diagnostic Strategy: MODS) followed by control (usual care), or control followed by intervention with 1 month of “wash-out” between the two periods. In the control period, the threshold will be as usual (500 ng/ml for patients aged 50 years or younger and age × 10 for older patients). In the MODS period, the threshold of D-dimers to rule out PE will be raised to 1000 ng/ml if no item of the YEARS score is present or will remain unchanged otherwise. Patients will be included if they have a suspicion of PE, defined as chest pain, dyspnea, or syncope. Non-inclusion criteria comprise a high clinical probability of PE or PERC-negative patients with low clinical probability.

Ethics and dissemination

The study has received the following approvals: Comité de protection des personnes Ile de France XI (France) and Comité de Ética de la Investigación con medicamentos del Hospital Clínic de Barcelona (Spain). Results will be made available to all included participants and other researchers.

Trial registration

ClinicalTrials.gov, NCT04032769. Registered on 24 July 2019.
Appendix
Available only for authorised users
Literature
1.
go back to reference American College of Emergency Physicians Clinical Policies Committee, Clinical Policies Committee Subcommittee on Suspected Pulmonary Embolism, Clinical policy: critical issues in the evaluation and management of adult patients presenting with suspected pulmonary embolism. Ann Emerg Med. 2003;41:257–70. https://doi.org/10.1067/mem.2003.40. American College of Emergency Physicians Clinical Policies Committee, Clinical Policies Committee Subcommittee on Suspected Pulmonary Embolism, Clinical policy: critical issues in the evaluation and management of adult patients presenting with suspected pulmonary embolism. Ann Emerg Med. 2003;41:257–70. https://​doi.​org/​10.​1067/​mem.​2003.​40.
10.
go back to reference Campbell MK, Piaggio G, Elbourne DR, et al. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661.CrossRef Campbell MK, Piaggio G, Elbourne DR, et al. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661.CrossRef
19.
24.
go back to reference Jac S, Pn B, Pa B, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21. https://doi.org/10.3310/hta21090. Jac S, Pn B, Pa B, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21. https://​doi.​org/​10.​3310/​hta21090.
Metadata
Title
MOdified DIagnostic strateGy to safely ruLe-out pulmonary embolism In the emergency depArtment: study protocol for the Non-Inferiority MODIGLIANI cluster cross-over randomized trial
Authors
Anne-Laure Philippon
Margaux Dumont
Sonia Jimenez
Sarah Salhi
Marine Cachanado
Isabelle Durand-Zaleski
Tabassome Simon
Yonathan Freund
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-020-04379-y

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue